Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000164945 | SCV000215634 | likely benign | Hereditary cancer-predisposing syndrome | 2014-07-14 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000232379 | SCV000282888 | likely benign | Ataxia-telangiectasia syndrome | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000164945 | SCV000682024 | likely benign | Hereditary cancer-predisposing syndrome | 2017-03-29 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000589366 | SCV000694205 | likely benign | not specified | 2021-07-26 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001357303 | SCV001828173 | benign | not provided | 2015-03-03 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000164945 | SCV002534066 | likely benign | Hereditary cancer-predisposing syndrome | 2020-11-09 | criteria provided, single submitter | curation | |
CHEO Genetics Diagnostic Laboratory, |
RCV003491895 | SCV004240391 | likely benign | Breast and/or ovarian cancer | 2023-06-22 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001357303 | SCV004563635 | likely benign | not provided | 2023-04-28 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV004589760 | SCV005083860 | benign | Familial cancer of breast | 2024-05-07 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |
Department of Pathology and Laboratory Medicine, |
RCV001357303 | SCV001552732 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The ATM p.Leu695= variant was identified in 2 of 5526 proband chromosomes (frequency: 0.00018) from individuals or families with breast cancer (Bernstein_2010, Rosenstein_2006). The variant was also identified in dbSNP (ID: rs786202229) as “With Likely benign allele”, ClinVar (as likely benign by Ambry Genetics, Invitae, and Color Genomics and as uncertain significance by Integrated Genetics), and Clinvitae (2x). The variant was not identified in the Cosmic, MutDB, LOVD 3.0, or ATM-LOVD databases. The variant was identified in control databases in 1 of 30948 chromosomes at a frequency of 0.000032 (Genome Aggregation Database Feb 27, 2017). It was observed in the “Other” population in 1 of 980 chromosomes (freq: 0.00102), but not in the African, Latino, European (Non-Finnish), Ashkenazi Jewish, East Asian, European (Finnish), and South Asian populations. The p.Leu695Leu variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. However, 3 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict the creation of a cryptic 3’ splice site; however, this information is not predictive enough to assume pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. | |
Natera, |
RCV000232379 | SCV002076965 | likely benign | Ataxia-telangiectasia syndrome | 2020-01-23 | no assertion criteria provided | clinical testing |